Description of Research Expertise:
Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials
CAR T cells
Selected Publications:
Cohen, A D., Garfall, A L., Stadtmauer, E A., Melenhorst, J. J, Lacey, Simon F., Lancaster, E, Vogl, D T., Weiss, B M., Dengel, K, Nelson, A, Plesa, G, Chen, F, Davis, M M., Hwang, Wei-Ting, Young, R M., Brogdon, J L., Isaacs, R, Pruteanu-Malinici, I, Siegel, D L., Levine, B L., June, C H., Milone, M C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma The Journal of Clinical Investigation : doi: 10.1172/JCI126397,2019.
Susanibar Adaniya, S P., Cohen, A D.*, Garfall, A L.*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications American Journal of Hematology doi: 10.1002/ajh.25428 (0): 2019.
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.: Elotuzumab enhances SLAMF7 interactions between natural killer and multiple myeloma cells to co-stimulate cytotoxicity. Cancer Immunology Research : 2019.
Fajgenbaum DC, Langan R-A, Japp AS, Shilling D, Partridge HL, Pierson SK, Singh A, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Betts M, Kambayashi T, Jordan MB, van Rhee F, Uldrick TS.: P13K/Akt/mTOR is a Novel Therapeutic Target in IL-6-blockade Refractory iMCD. Journal of Clinical Investigation : 2019.
Cornell RF, Ky B, Weiss BM, Dahm C, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith Am, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Events during Proteastome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology : 2019.
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma Cancer Immunology Research 7 (4): 658-669,2019.
Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer Journal 9 (4): 37,2019.
Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melenhorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma Blood Advances : 2019.
L Bernabei, A L. Garfall, J. J Melenhorst, S F Lacey, E A. Stadtmauer, D T. Vogl, V Gonzalez, G Plesa, R M Young, A Waxman, B L Levine, C H June, M C. Milone, and A D. Cohen: PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after BCMA-Directed CAR T Cells Blood, ASH Annual Meeting, San Diego, CA 132 : #1973,2018.
A.D. Cohen: CAR T-cell therapy against B-cell maturation antigen in multiple myeloma Clinical Advances in Hematology and Oncology 16 (12): 804-806,2018.